Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029?
Health & MedicineOne-Off2a
Manifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoPrevisione della comunità attuale
Sì 79.5%
Previsori
5
Tipo di domanda
binary
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Dati di mercato
Aggiornato 18 ore fa
Obsoleto30 giu 24, 16:24 UTC31 dic 28, 22:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
Will ME/CFS blood test replicate in larger study?
Manifold MarketsWill the finding of high WASF3 in ME/CFS (Hwang,PNAS, 2023) be successfully replicated by the end of 2027?
Manifold MarketsCommercially available tooth regeneration therapy
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiFDA approves skin cancer vaccine by which date?
PolymarketRegole
In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.
- This goes against nearly every other major organisation, whom say that exercise therapy is harmful for people with ME/CFS:
- CDC (Since 2017) (US)
- NICE and NHS (since 2021) (UK)
- Mayo Clinic (Since 2024) (US)
- Australian ME/CFS Guidelines (Since 2024) (Australia)
Mercati aperti
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 20,3K €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+0.6pt4%
- Volume totale
- 1,6 Mln €
- Volume 24h
- 8K €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+4.0pt65%
- September41%
- June28%
- Volume totale
- 84,1K €
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume totale
- 652,6K €
- Volume 24h
- 3,4K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-4.0pt58%
+2 altri esiti
- Volume totale
- 865,4K €
- Volume 24h
- 3K €
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volume totale
- 915,2K €
- Volume 24h
- 1,2K €
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Measles cases in U.S. in 2026?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Domande frequenti
- Quali sono le probabilità attuali per Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- Manifold Markets quota Yes al 80% al 8 settembre 2026.
- Quando si risolve Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? dovrebbe risolversi il 31 dicembre 2028.
- Come viene liquidato Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- Manifold Markets liquida questo mercato come segue: In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.